CLAIMS:

1) An antiparasitic formulation characterized in that it comprises, as active ingredients, spinosyn(s) in combination with a compound of formula (I)

5

10

20

35

$$\begin{array}{c|c} W & CH_2 \\ \hline N & R_4 & R_3 \end{array} \tag{I}$$

and salts thereof, in which

Ar is 2,6-dichloro-4- trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl; 15

A is S(O)_m, -CH=CH-, O or NH;

W is N and Z is CR5; or W is CR1 and Z is N or CR5;

R¹ is hydrogen, optionally substituted alkyl, halogen or R²⁰S(O)_a:

R² and R³ are hydrogen, alkyl, alkenyl or alkynyl, each of which is optionally

substituted, aryl, cyano, halogen, nitro, YR20, S(O)2NR8R9, CHO, NR8R9 or CYNR8R9;

R4 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl or optionally substituted alkoxycarbonyl;

R⁵ is hydrogen, alkyl, optionally substituted amino or halogen;

R⁸ and R⁹ are the same or different and are hydrogen, optionally substituted alkyl,

25 acyl or aryl;

R²⁰ is optionally substituted alkyl;

Y is O or S;

m is 0, 1 or 2;

p is 0 or 1;

30 n is 0, 1 or 2; and

q is 0, 1 or 2,

and in which a) any alkyl, alkoxy and alkylthio groups is of 1 to 4 carbon atoms; b) any alkenyl or alkynyl groups is of 2 to 5 carbon atoms; c) any substituted alkyl, alkoxy, alkylthio, alkenyl or alkynyl group is substituted by one or more of the same or different groups selected from halogen, YR²⁰, dihalocyclopropyl, cyano, nitro, optionally substituted amino, acyloxy and aryl; d) any aryl group is phenyl, optionally substituted, by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, haloalkylsulphonyl, cyano or nitro; e) any acyl group is alkanoyl of 1 to 4 carbon atoms, or alkylsulphonyl or haloalkylsulphonyl; and f) any optionally substituted amino groups is of formula NR8R9, with the proviso that when W is CR1 and Z is CR5

40 and n and p are both 0, R4 is not alkyl. 15

20

- 2) The formulation according to claim 1 characterized in that the compound of formula (I) is 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (compound 22c).
- 5 3) The formulation according to claim 1 or 2 characterized in that the spinosyns are a mixture of any two or more spinosyn compounds.
 - 4) The formulation according to claim 3 characterized in that the mixture is spinosad.
- 5) The formulation according to any of claims 1-4 characterized in that the compound of formula (I) and one or more spinosyns are present in a ratio of 1:10 to 10:1.
 - 6) Use of one or more spinosyns and at least one compound according to formula 1 as active ingredients in the manufacture of a medicament for controlling an ectoparasite infestation by administering the active ingredients in combination, either simultaneously or sequentially.
 - 7) Use according to claim 6 wherein the active ingredients are 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole and spinosad.
 - 8) Use according to claim 6 or 7, wherein the medicament is for controlling an ectoparasite infestation by administering the active ingredients simultaneously.
 - Use according to claim 8, wherein the medicament comprises the active ingredients in a single preparation.
 - 10) Use according to claim 6 wherein the ectoparasites are ticks.
 - 11) Use according to claim 6 wherein the ectoparasites are fleas.